The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
Open accessAbstract
ARID1A is a recently identified tumor suppressor gene that is mutated in approximately 50% of ovarian clear cell and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry. In this study, we evaluated ARID1A immunoreactivity in a wide variety of carcinomas to determine the prevalence of ARID1A inactivation in carcinomas. Mutational analysis of ARID1A was carried out in selected cases. Immunoreactivity was not detected (corresponding to inactivation or mutation of ARID1A) in 36 (3.6%) of 995 tumors. Uterine low-grade endometrioid carcinomas showed a relatively high-frequency loss of ARID1A expression, as 15 (26%) of 58 cases were negative. The other tumor that had a relatively high-frequency loss of ARID1A expression was gastric carcinoma (11%). Mutational analysis showed 10 (40%) of 25 uterine endometrioid carcinomas; none of 12 uterine serous carcinomas and none of 56 ovarian serous and mucinous carcinomas harbored somatic ARID1A mutations. All mutations in endometrioid carcinomas were nonsense or insertion/deletion mutations, and tumors with ARID1A mutations showed complete loss or clonal loss of ARID1A expression. In conclusion, this study is the first large-scale analysis of a wide variety of carcinomas showing that uterine low-grade endometrioid carcinoma is the predominant tumor type harboring ARID1A mutations and frequent loss of ARID1A expression. These findings suggest that the molecular pathogenesis of low-grade uterine endometrioid carcinoma is similar to that of ovarian low-grade endometrioid and clear cell carcinoma, tumors that have previously been shown to have a high-frequency loss of expression and mutation of ARID1A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 3×
“These genes include JARID1C in renal cell carcinoma,(1) BRG1 (SMARCA4) in lung carcinoma,(12,16) and, most recently, ARID1A in ovarian clear cell and ovarian low-grade endometrioid carcinoma.(6,21) The findings in this study extend previous observations and provide cogent evidence that epigenetic changes, like genetic…”
BackgroundSelf-citationKinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386761a0 · Cited by 1,240
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Self-citationShih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationSystematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · cited 1×
“These genes include JARID1C in renal cell carcinoma (1), BRG1 (SMARCA4) in lung carcinoma (12,16) and, most recently, ARID1A in ovarian clear cell and ovarian low-grade endometrioid carcinoma (6,21).”
BackgroundChromatin remodelling during development
Ho, L., & Crabtree, G. R. (2010) · Nature · doi:10.1038/nature08911 · Cited by 1,114 · cited 2×
“has been shown to play an integral role in controlling gene expression(19) and is critical in tissue development, cellular differentiation, and tumor suppression.(3,4,15) ARID1A is essential for SWI/SNF complexes to suppress DNA synthesis.”
BackgroundWang, E.-Y., & Li, S.-Y. (1990) · Cited by 884
Identification of a Gene Located at Chromosome 5q21 that Is Mutated in Colorectal Cancers
Kinzler, K. W., Nilbert, M. C., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hamilton, S. R., Hedge, P., Markham, A., et al. (1991) · Science · doi:10.1126/science.1848370 · Cited by 756
The SWI/SNF complex and cancer
Reisman, D., Glaros, S., & Thompson, E. A. (2009) · Oncogene · doi:10.1038/onc.2009.4 · Cited by 568
Gao, X., Tate, P., Hu, P., Tjian, R., Skarnes, W. C., & Wang, Z. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801802105 · Cited by 336
Cited by
Kadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,458
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 910
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
Wang, K., Kan, J., Yuen, S. T., Shi, S. T., Chu, K. M., Law, S., Chan, T. L., Kan, Z., Chan, A. S. Y., Tsui, W. Y., et al. (2011) · Nature Genetics · doi:10.1038/ng.982 · Cited by 771
Cancer-associated mutations in endometriosis without cancer
Anglesio, M. S., Papadopoulos, N., Ayhan, A., Nazeran, T. M., Noë, M., Horlings, H. M., Lum, A., Jones, S., Senz, J., Seckin, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614814 · Cited by 628
Self-citationARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
Wu, J. N., & Roberts, C. W. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0361 · Cited by 456
The Origin and Pathogenesis of Endometriosis
Wang, Y., Nicholes, K., & Shih, I.-M. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032654 · Cited by 455
Self-citationGuan, B., Wang, T.-L., & Shih, I.-M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1562 · Cited by 442
Self-citationNIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Le Gallo, M., O'Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O'Neil, N. J., Price, J. C., Zhang, S., England, B. M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 419
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ
Chang, L., Azzolin, L., Di Biagio, D., Zanconato, F., Battilana, G., Lucon Xiccato, R., Aragona, M., Giulitti, S., Panciera, T., Gandin, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0658-1 · Cited by 327
New concepts for an old problem: the diagnosis of endometrial hyperplasia
Sanderson, P. A., Critchley, H. O. D., Williams, A. R. W., Arends, M. J., & Saunders, P. T. K. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw042 · Cited by 323
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Murali, R., Davidson, B., Fadare, O., Carlson, J. A., Crum, C. P., Gilks, C. B., Irving, J. A., Malpica, A., Matias-Guiu, X., McCluggage, W. G., et al. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000491 · Cited by 278
The emerging roles of ARID1A in tumor suppression
Wu, R.-C., Wang, T.-L., & Shih, I.-M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28411 · Cited by 261
Self-citationYamamoto, S., Tsuda, H., Takano, M., Tamai, S., & Matsubara, O. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.189 · Cited by 259
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Mandal, J., Mandal, P., Wang, T.-L., & Shih, I.-M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00856-5 · Cited by 84
“Other mechanisms that are affected due to ARID1A loss are defective control of cell cycle progression, DNA damage checkpoint, regulation of p53 downstream targets (CDKN1A and SMAD3), and regulation of telomerase activity [31, 32].”
Self-citationFuningana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.008 · Cited by 23
Metadata
- Authors
- Guan, B., Mao, T.-L., Panuganti, P. K., Kuhn, E., Kurman, R. J., Maeda, D., Chen, E., Jeng, Y.-M., Wang, T.-L., & Shih, I.-M.
- Venue
- American Journal of Surgical Pathology
- Published
- 2011-05
- Volume
- 35
- Issue
- 5
- Pages
- 625-632
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2075053675
- Cited by
- 286
- References
- 18
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.